Category: “Research Findings”

Penn Medicine’s Colton Center Is Driving the Next Immunotherapy Revolution — This Time for Autoimmune Disease

https://www.coltonconsortium.org/news/penn-medicines-colton-center-is-driving-the-next-immunotherapy-revolution-this-time-for-autoimmune-disease/

Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.

Lupus Flare-Ups Strongly Linked to Specific Bacterial Growth in Gut

https://www.coltonconsortium.org/news/lupus-flare-ups-strongly-linked-to-specific-bacterial-growth-in-gut/

NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.

Yale Researchers Use Skin as a Window Into Autoimmune Disease — and a Path to Better Treatments

https://www.coltonconsortium.org/news/yale-researchers-use-skin-as-a-window-into-autoimmune-disease-and-a-path-to-better-treatments/

Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.

How Lupus Antibodies Sabotage a Key Enzyme — and What It Means for Treating Kidney Disease

https://www.coltonconsortium.org/news/how-lupus-antibodies-sabotage-a-key-enzyme-and-what-it-means-for-treating-kidney-disease/

Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.